Diagnostic Center | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Subscribe To Our Newsletter & Stay Updated
